Johnson & Johnson MedTech (J&J MedTech), a leading player in medical technology, has entered into an exclusive distribution and promotional agreement with CG Bio and its subsidiary CG MedTech for the commercialization of NOVOSIS, an advanced bone graft product. The partnership aims to improve surgical outcomes in trauma and spinal procedures by broadening access to innovative orthopedic solutions across key markets in Asia.
Under the terms of the agreement, J&J MedTech will hold exclusive distribution rights for NOVOSIS in four Asian countries and select regions of China, including South Korea, Taiwan, Thailand, India, Hong Kong, and Macau. In South Korea, the company will specifically distribute NOVOSIS Trauma, a CG MedTech product developed for trauma-related bone treatments.
The deal was officially signed at CG Bio’s smart manufacturing facility, S-Campus, in Hwaseong, Gyeonggi Province, with the participation of Vishnu Kalra, Chairman of J&J MedTech Asia Pacific, and Yu Hyun-seung, CEO of CG Bio.
NOVOSIS is a next-generation bone substitute that combines recombinant human bone morphogenetic protein-2 (rhBMP-2) with hydroxyapatite ceramic. It is used for treating acute fractures in the upper and lower limbs and plays a key role in spinal fusion surgeries involving implants. The hydroxyapatite ceramic acts as a scaffold to support bone regeneration, while its slow-release technology enhances therapeutic effectiveness. To date, NOVOSIS has been utilized in approximately 100,000 procedures worldwide.
“Musculoskeletal conditions affect millions across the Asia-Pacific region, and this collaboration with CG Bio reinforces our commitment to driving innovation and elevating healthcare standards,” said Vishnu Kalra. “J&J MedTech remains at the forefront of biomaterial solutions that enhance surgical planning, shorten operating times, and accelerate patient recovery.”
Oh Jin-yong, Managing Director of J&J MedTech North Asia, emphasized that the partnership marks a significant milestone in integrating Korean medical innovation into global orthopedic advancements. “By incorporating CG Bio’s cutting-edge technology, we are not only refining surgical protocols but also ensuring that patient care remains at the core of our mission,” he said. He also noted that this alliance underscores J&J MedTech’s dedication to strengthening local healthcare systems while expanding the global reach of pioneering Korean medical solutions.